|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600118096 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-02 11:03:03 |
|
注册时间: Date of Registration: |
2026-02-02 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
孤独症儿童康复信息平台及产品应用验证 |
|
Public title: |
Validation of Rehabilitation Information Platform and Product Applications for Children with Autism Spectrum Disorder |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
孤独症儿童康复信息平台及产品应用验证 |
|
Scientific title: |
Validation of Rehabilitation Information Platform and Product Applications for Children with Autism Spectrum Disorder |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
代英 |
研究负责人: |
代英 |
|
Applicant: |
Dai Ying |
Study leader: |
Dai Ying |
|
申请注册联系人电话: Applicant telephone: |
+86 23 6837 0551 |
研究负责人电话: Study leader's telephone: |
+86 23 6837 0551 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
dai@hospital.cqmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
dai@hospital.cqmu.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区中山二路136号 |
研究负责人通讯地址: |
重庆市渝中区中山二路136号 |
|
Applicant address: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing, China |
Study leader's address: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆医科大学附属儿童医院 |
||
|
Applicant's institution: |
Children's Hospital of Chongqing Medical University |
||
|
研究负责人所在单位: |
重庆医科大学附属儿童医院 |
||
|
Affiliation of the Leader: |
Children's Hospital of Chongqing Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2024)年伦审(临研)第(8)号;(2024)年伦审(临研)第(8-1)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆医科大学附属儿童医院医学研究伦理委员会 |
||
|
Name of the ethic committee: |
Institutional Review Board Children's Hospital of Chongqing Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-13 00:00:00 |
||
|
伦理委员会联系人: |
蔡诗容 |
||
|
Contact Name of the ethic committee: |
Cai Shirong |
||
|
伦理委员会联系地址: |
重庆市渝中区中山二路136号 |
||
|
Contact Address of the ethic committee: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 68370035 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
741223671@qq.com |
|
研究实施负责(组长)单位: |
重庆医科大学附属儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Children's Hospital of Chongqing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区中山二路136号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 136, Zhongshan 2nd Road, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program |
||||||||||||||||||||||
|
Target disease: |
Autism spectrum disorder |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本课题组拟通过对所研发的孤独症儿童康复产品和康复管理信息平台进行临床应用验证,评估康复产品及信息平台的有效性和安全性,为孤独症儿童的个性化、智能化治疗提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
The research team intends to conduct clinical application validation of the developed rehabilitation products and management information platform for children with autism spectrum disorder (ASD), aiming to evaluate the efficacy and safety of these rehabilitation solutions and the information platform. This initiative will provide an empirical foundation for personalized and intelligent therapeutic interventions for children with ASD. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.ASD儿童:年龄在2-6岁,经行为发育医师评估有发育异常表现,符合美国精神障碍诊断统计手册第5版(DSM-5)关于ASD的诊断标准,结合ADOS、CARS、SRS、ABC、改良婴幼儿孤独症量表(Modified Checklist For Autism In Toddlers,M-CHAT)确诊ASD的儿童; |
||||||||||||||||||||||
|
Inclusion criteria |
1.Children with ASD, aged 2-6 years, who had developmental abnormalities as assessed by behavioral development physicians and met the Diagnostic Statistical Manual of Mental Disorders 5th Edition (DSM-5) diagnostic criteria for ASD, Children with ASD were diagnosed with ADOS, CARS, SRS, ABC, and Modified Checklist For Autism In Toddlers (M-CHAT). |
||||||||||||||||||||||
|
排除标准: |
1.其他已知的严重神经精神疾病,染色体、遗传代谢性疾病及其他重大躯体疾病,如视听障碍、癫痫、苯丙酮尿症、结节性硬化、神经纤维瘤、严重脑外伤等疾病; 2.监护人不愿参与研究者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Other known severe neuropsychiatric disorders, chromosomal, genetic metabolic diseases, and other major physical diseases, such as visual and auditory impairments, epilepsy, phenylketonuria, tuberous sclerosis, neurofibromatosis, severe traumatic brain injury, and other conditions; 2. Guardians unwilling to participate in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-15 00:00:00至 To 2026-11-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-07-10 00:00:00 至 To 2026-11-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签 |
|
Blinding: |
Open-label |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026.11.30(www.medresman.org.cn) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2026.11.30(www.medresman.org.cn) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF, EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF, EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |